SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Dynavax DVAX
DVAX 10.40+1.0%Oct 30 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche5/17/2018 1:24:17 PM
  Read Replies (1) of 184
 
One intent is to include weakly antigenic cancers under the pembro umbrella, and even the ITT data is encouraging. An incremental increase in long-term survival would be a big deal.

Half of responders were detected at or after the day 127 scan, and early dropouts with progressive disease never made it to the day 64 scan. Sort of natural that the investigators would focus on per protocol. And, if late responses were one reason to progress to pivotal testing, early withdrawals wouldn't be a particular issue?

Not proposing that anyone rush out and buy, but "context matters".

edit: Abstract wording is interesting. They point to the three patients with progressive disease who were dropped from PP, and those patients never arrived at day 64. But they specify "half of responses were observed greater than or equal to D127 with early discontinuation from PD occurring before D127". Thus there may be more than three patients who dropped out with early PD, somewhere between day 64 and 127.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News